Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut

Key Terms

multi-agentic technical

Multi-agentic describes a therapy, product, or strategy that uses two or more active agents—such as drugs, biological components, or treatment modalities—intended to work together toward a single therapeutic or functional goal. For investors, multi-agentic approaches can change effectiveness, safety, regulatory hurdles, development cost and patent strategy—think of combining ingredients in a recipe to get a stronger result, but one that requires more testing and coordination.

clinical trial registries regulatory

Lists or databases where medical studies of new drugs, devices or treatments are publicly recorded, including basic goals, who runs them, locations and trial status. They matter to investors because registries provide an early, verifiable signal of clinical activity and timelines—like a public construction permit log for drug development—helping assess the credibility, progress and potential timing of future regulatory approvals or setbacks.

biomedical literature medical

Biomedical literature is the body of published research, studies, reviews and clinical reports about biology, diseases, treatments and medical devices. For investors it functions like a technical map or progress report: it reveals whether a therapy or product appears to work, how safe it seems, and how regulators and medical professionals are likely to view it, information that directly influences a company’s prospects, valuation and risk.

admet medical

ADMET is the shorthand for a drug candidate’s absorption, distribution, metabolism, excretion and toxicity — the key ways it behaves and is processed in the body. Investors watch ADMET because favorable results indicate a medicine is likely to reach its target, be safe enough, and survive development and regulatory review; poor ADMET is a common, early reason a program fails, like a car that looks good but won’t run reliably or safely.

blood-brain barrier medical

A protective barrier of tightly packed cells and supporting tissue that controls what substances in the blood can enter the brain, acting like a security checkpoint that keeps out most pathogens and many drugs while allowing essential nutrients through. For investors, the barrier matters because whether a therapy can cross or safely bypass it often determines clinical success, regulatory approval and commercial potential for treatments of brain disorders.

structure-activity relationship (sar) medical

Structure-activity relationship (SAR) is the connection between a molecule’s physical make-up—its shape and chemical pieces—and how well it produces a desired biological effect. For investors, SAR maps act like a recipe guide that shows which changes to a compound are likely to make a drug more effective, safer, or easier to manufacture, helping estimate development risk, potential costs, timelines, and the value of a drug program.

ontology technical

An ontology is an organized map of concepts and the rules that show how pieces of information are related, so different systems and people can understand the same thing the same way. For investors, it matters because a clear map makes it easier to compare companies, automate analysis, spot inconsistencies, and meet reporting or regulatory requirements—think of it as a consistent filing system that helps turn messy data into reliable decisions.

generative ai technical

Generative AI is a type of computer technology that can create new content, like text, images, or music, on its own. It’s important because it can produce realistic and useful material quickly, which could change how we create art, write stories, or even develop new products. Think of it as a smart robot that can invent and produce things almost like a human.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• CEO Panna Sharma to Lead Live, Unscripted Platform Walkthrough in Two Interactive Sessions on April 30, 2026 — Open to Investors, Researchers, and the Global Biomedical Community
• Registration Link & Details Can be Accessed Below

DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN) (“Lantern” or the “Company”), an AI-driven clinical-stage precision oncology company, today announced the first public demonstration of withZeta.ai, its multi-agentic AI co-scientist platform, to be held on Thursday, April 30, 2026. The event follows the platform's scientific community debut at the American Association for Cancer Research (AACR) Annual Meeting 2026 and its initial unveiling at Nasdaq MarketSite — and marks the first time the platform will be demonstrated live and without restriction to a global public audience of investors, researchers, and industry participants.

President and Chief Executive Officer Panna Sharma will lead the demonstration in real time — live, interactive, and unrehearsed — showing how withZeta.ai operates as a genuine AI co-scientist at the frontier of oncology drug discovery. Two identical sessions will be held to accommodate global time zones:

• Morning Session: 8:30 AM ET — Register Here
• Afternoon Session: 4:30 PM ET — Register Here

Each session will include a live platform walkthrough followed by an open Q&A with management.

From Scientific Validation to Public Stage

withZeta.ai made its scientific debut at AACR 2026 — one of the world's most rigorous forums for oncology and translational research — and was first unveiled at Nasdaq MarketSite, a globally recognized venue at the intersection of capital markets and innovation. April 30th represents a deliberate next step: opening the platform to the full public for the first time, with no gatekeeping, no curated excerpts, and no pre-recorded footage.

Attendees will watch in real time as the platform executes complex research workflows — synthesizing clinical, molecular, and scientific datasets simultaneously to generate insights and compress research timelines that historically required months of manual effort. This is not a product marketing event. It is a transparency event, and the platform will speak for itself.

A Platform Built for the Economics and Urgency of Rare Cancer

With the AI-driven drug discovery market projected to surpass $15 billion by 2030 and growing at over 30% annually, the industry is in the early stages of a structural transformation. Yet rare cancers remain the discipline's most persistent blind spot — historically neglected not for lack of scientific interest, but because the economics and timelines of traditional development make them commercially unattractive.

withZeta.ai was purpose-built to close that gap. The platform integrates:

• A proprietary rare cancer ontology spanning hundreds of cancer subtypes, structuring biological knowledge in a form that AI agents can actively reason across — not merely retrieve.
• Multi-database querying across clinical trial registries, biomedical literature, and molecular datasets — simultaneously and in real time, not sequentially.
• Advanced generative AI models for molecular design, ADMET prediction, blood-brain barrier permeability analysis, and structure-activity relationship (SAR) evaluation — capabilities embedded in the platform’s Ether0 generative chemistry architecture.
• A scalable, subscription-based commercial model — with introductory, academic, and enterprise tiers — representing a non-dilutive, recurring revenue stream accessible to any researcher, institution, or biopharma organization globally.

Following its debut at Nasdaq MarketSite and AACR 2026, Lantern is advancing withZeta.ai as both a scientific accelerator and a commercial growth engine — one that creates value for rare cancer patients, for research institutions, and for Lantern shareholders simultaneously.

“The rarest cancers have always faced the longest waits — not because the science is absent, but because the infrastructure to move at the speed of urgency has never existed. withZeta.ai changes that. It is not a search engine, not a literature tool, and not a chatbot with oncology data loaded in. It is a multi-agentic AI-powered co-scientist, forged from years of real clinical development, careful curation of knowledge-bases and exquisite disease models. It is capable of executing research workflows and drug development decision making and assessment in real time - things that would otherwise take months or longer. On April 30th, we are inviting the world to see it operate — live, unrehearsed, and without restriction.”

— Panna Sharma, President and Chief Executive Officer, Lantern Pharma Inc.

Webinar Access Details

Date: Thursday, April 30, 2026

Morning Session: 8:30 AM ET

• Registration: Register for Morning Session

Afternoon Session: 4:30 PM ET

• Registration: Register for Afternoon Session

Subscribe Now: withZeta.ai

ABOUT LANTERN PHARMA INC.

Lantern Pharma Inc. (Nasdaq: LTRN) is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR® platform to transform the development of cancer therapies. Lantern’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic cancers and sarcomas), and LP-300 which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed as STAR-001 for pediatric and adult CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary. withZeta.ai, Lantern’s multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the Company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.

ABOUT withZeta.ai

withZeta.ai is redefining how rare cancer research, discovery, drug development, and clinical trial design gets done. Knowledge work in oncology is migrating to AI co-scientists — autonomous systems that investigate, reason, and synthesize across the full breadth of scientific evidence. withZeta.ai is that co-scientist: purpose-built for the biology, economics, and urgency of rare cancer drug development, and accessible to any researcher, anywhere. Built by Lantern Pharma (Nasdaq: LTRN). Learn more and subscribe at withZeta.ai.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform and withZeta.ai platform in identifying drug candidates, accelerating drug development, and generating revenue through software licensing and subscription models; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; the planned commercialization of our AI platforms including withZeta.ai and the expected market opportunity for AI co-scientist platforms; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others.

Any statements that are not statements of historical fact (including, without limitation, statements that use words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “model,” “objective,” “aim,” “upcoming,” “should,” “will,” “would,” or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, (vii) the risk that our AI platform commercialization efforts, including withZeta.ai, may not generate the anticipated revenue or achieve the expected market adoption, and (viii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 30, 2026.

You may access our Annual Report on Form 10-K for the year ended December 31, 2025 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC’s website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260424944945/en/

Investor Inquiries: ir@lanternpharma.com | +1-972-277-1136

Source: Lantern Pharma Inc.